Abstract Psoriasis and psoriatic arthritis (PsA) are chronic inflammatory diseases, affecting patients’ quality of life, particularly when involving difficult-to-treat areas. While randomized controlled trials (RCTs) have shown that ixekizumab is effective for psoriatic disease, real-world evidence (RWE) is essential for assessing its broader applicability. This retrospective, single-center study evaluated the effectiveness and safety of ixekizumab in 37 Greek patients with psoriasis and/or PsA, including involvement of difficult-to-treat areas, over 52 weeks of treatment. Ixekizumab led to significant and sustained improvements in skin disease up to week 52. Joint manifestations and difficult sites showed marked improvement, as did patient-reported quality of life. Biologic-naïve patients and those with early disease onset showed better responses. No serious adverse events were reported, and cardiovascular parameters remained stable. These findings support ixekizumab’s strong efficacy and safety in routine clinical use, including patients with prior biologic exposure and complex disease, reinforcing its role as a cornerstone therapy.
Vaiopoulos et al. (Sat,) studied this question.